Table of Contents Author Guidelines Submit a Manuscript
AIDS Research and Treatment
Volume 2015, Article ID 923194, 11 pages
http://dx.doi.org/10.1155/2015/923194
Research Article

Ascertainment and Verification of End-Stage Renal Disease and End-Stage Liver Disease in the North American AIDS Cohort Collaboration on Research and Design

1Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA 98109, USA
2Center for AIDS Research, University of Washington, Seattle, WA 98104, USA
3Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA
4Division of Infectious Diseases Chronic Viral Illness Service, Department of Medicine, McGill University, Montreal, QC, Canada
5Department of Medicine, Johns Hopkins University, Baltimore, MD 21287, USA
6Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia VA Medical Center, Philadelphia, PA 19104, USA
7Medical Education and Biomedical Informatics, School of Medicine, University of Washington, Seattle, WA 98109, USA
8Biobehavioral Nursing and Health Systems, Department of Nursing, University of Washington, Seattle, WA 98195, USA

Received 15 December 2014; Accepted 16 January 2015

Academic Editor: Glenda Gray

Copyright © 2015 Mari M. Kitahata et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. J. Palella Jr., R. K. Baker, A. C. Moorman et al., “Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study,” Journal of Acquired Immune Deficiency Syndromes, vol. 43, no. 1, pp. 27–34, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. The Antiretroviral Therapy Cohort Collaboration (ART-CC), “Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies,” The Lancet, vol. 372, no. 9635, pp. 293–299, 2008. View at Publisher · View at Google Scholar
  3. N. Lohse, A.-B. E. Hansen, G. Pedersen et al., “Survival of persons with and without HIV infection in Denmark, 1995–2005,” Annals of Internal Medicine, vol. 146, no. 2, pp. 87–95, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. E. Losina, B. R. Schackman, S. N. Sadownik et al., “Racial and sex disparities in life expectancy losses among hiv-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy,” Clinical Infectious Diseases, vol. 49, no. 10, pp. 1570–1578, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. J. S. Currier, J. D. Lundgren, A. Carr et al., “Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy,” Circulation, vol. 118, no. 6, pp. e29–e35, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. V. A. Triant, H. Lee, C. Hadigan, and S. K. Grinspoon, “Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 7, pp. 2506–2512, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. C. J. Achenbach, S. R. Cole, M. M. Kitahata et al., “Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy,” AIDS, vol. 25, no. 5, pp. 691–700, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Lucas, Y. Jing, M. Sulkowski et al., “Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals,” The Journal of Infectious Diseases, vol. 208, no. 8, pp. 1240–1249, 2013. View at Publisher · View at Google Scholar
  9. E. L. Yanik, S. Napravnik, S. R. Cole et al., “Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy,” Clinical Infectious Diseases, vol. 57, no. 5, pp. 756–764, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. J. C. Trullas, A. Mocroft, F. Cofan et al., “Dialysis and renal transplantation in HIV-infected patients: a European survey,” Journal of Acquired Immune Deficiency Syndromes, vol. 55, no. 5, pp. 582–589, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Ryom, O. Kirk, J. Lundgren et al., “Advanced chronic kidney disease, end-stage renal disease and renal death among HIV-positive individuals in Europe,” HIV Medicine, vol. 14, no. 8, pp. 503–508, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. A. I. Choi, R. A. Rodriguez, P. Bacchetti, D. Bertenthal, P. A. Volberding, and A. M. O'Hare, “The impact of HIV on chronic kidney disease outcomes,” Kidney International, vol. 72, no. 11, pp. 1380–1387, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Posthouwer, M. Makris, T. T. Yee et al., “Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort study,” Blood, vol. 109, no. 9, pp. 3667–3671, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. J. J. Goedert, M. Elaine Eyster, M. M. Lederman et al., “End-stage liver disease in persons with hemophilia and transfusion-associated infections,” Blood, vol. 100, no. 5, pp. 1584–1589, 2002. View at Google Scholar · View at Scopus
  15. The White House Office of National AIDS Policy, The National HIV/AIDS Strategy, The White House Office of National AIDS Policy, 2010.
  16. NIH Office of AIDS Research, FY 2013 Trans-NIH Plan for HIV-Related Research, 2013.
  17. M. B. Klein, K. C. Rollet, S. Saeed et al., “HIV and hepatitis C virus coinfection in Canada: challenges and opportunities for reducing preventable morbidity and mortality,” HIV Medicine, vol. 14, no. 1, pp. 10–20, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Goldberg, J. D. Lewis, S. D. Halpern, M. Weiner, and V. Lo Re III, “Validation of three coding algorithms to identify patients with end-stage liver disease in an administrative database,” Pharmacoepidemiology and Drug Safety, vol. 21, no. 7, pp. 765–769, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. C. McAdam-Marx, L. J. McGarry, C. A. Hane, J. Biskupiak, B. Deniz, and D. I. Brixner, “All-Cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective,” Journal of Managed Care Pharmacy, vol. 17, no. 7, pp. 531–546, 2011. View at Google Scholar · View at Scopus
  20. A. Lifson, W. Belloso, R. Davey et al., “Development of diagnostic criteria for serious non-AIDS events in HIV clinical trials,” HIV Clinical Trials, vol. 11, no. 4, pp. 205–219, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. E. Rosenthal, D. Salmon-Céron, C. Lewden et al., “Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 Study in collaboration with the Mortalité 2005 survey, ANRS EN19),” HIV Medicine, vol. 10, no. 5, pp. 282–289, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. M. V. Ragni, M. A. Nalesnik, R. Schillo, and Q. Dang, “Highly active antiretroviral therapy improves ESLD-free survival in HIV-HCV co-infection,” Haemophilia, vol. 15, no. 2, pp. 552–558, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Murillas, A. Rimola, M. Laguno et al., “The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study,” Liver Transplantation, vol. 15, no. 9, pp. 1133–1141, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Baillargeon, R. D. Soloway, D. Paar et al., “End-stage liver disease in a state prison population,” Annals of Epidemiology, vol. 17, no. 10, pp. 808–813, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. N. Merchante, J. A. Girón-González, M. González-Serrano et al., “Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease,” AIDS, vol. 20, no. 1, pp. 49–57, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. J. J. Goedert, A. Hatzakis, K. E. Sherman, and M. E. Eyster, “Lack of association of hepatitis C virus load and genotype with risk of end-stage liver disease in patients with human immunodeficiency virus coinfection,” Journal of Infectious Diseases, vol. 184, no. 9, pp. 1202–1205, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. M. V. Ragni and S. H. Belle, “Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection,” Journal of Infectious Diseases, vol. 183, no. 7, pp. 1112–1115, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. V. Jotwani, Y. Li, C. Grunfeld, A. I. Choi, and M. G. Shlipak, “Risk factors for ESRD in HIV-infected individuals: traditional and HIV-related factors,” The American Journal of Kidney Diseases, vol. 59, no. 5, pp. 628–635, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. A. I. Choi, Y. Li, C. Parikh, P. A. Volberding, and M. G. Shlipak, “Long-term clinical consequences of acute kidney injury in the HIV-infected,” Kidney International, vol. 78, no. 5, pp. 478–485, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. A. I. Choi, R. A. Rodriguez, P. Bacchetti, D. Bertenthal, P. A. Volberding, and A. M. O'Hare, “Racial differences in end-stage renal disease rates in HIV infection versus diabetes,” Journal of the American Society of Nephrology, vol. 18, no. 11, pp. 2968–2974, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. G. M. Lucas, B. Lau, M. G. Atta, D. M. Fine, J. Keruly, and R. D. Moore, “Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races,” Journal of Infectious Diseases, vol. 197, no. 11, pp. 1548–1557, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. S. K. Gupta, J. A. Eustace, J. A. Winston et al., “Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America,” Clinical Infectious Diseases, vol. 40, no. 11, pp. 1559–1585, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. T. Brown, S. Cole, X. Li et al., “Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study,” Archives of Internal Medicine, vol. 165, no. 10, pp. 1179–1184, 2005. View at Google Scholar
  34. E. C. Seaberg, A. Muñoz, M. Lu et al., “Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003,” AIDS, vol. 19, no. 9, pp. 953–960, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Tsui, E. Vittinghoff, K. Anastos et al., “Hepatitis C seropositivity and kidney function decline among women with HIV: data from the Women’s Interagency HIV Study,” American Journal of Kidney Diseases, vol. 54, no. 1, pp. 43–50, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. S. E. Kellerman, D. L. Hanson, A. D. McNaghten, and P. L. Fleming, “Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects,” The Journal of Infectious Diseases, vol. 188, no. 4, pp. 571–577, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. M. L. Rodríguez-Méndez, A. González-Quintela, A. Aguilera, and E. Barrio, “Prevalence, patterns, and course of past hepatitis B virus infection in intravenous drug users with HIV-1 infection,” The American Journal of Gastroenterology, vol. 95, no. 5, pp. 1316–1322, 2000. View at Publisher · View at Google Scholar · View at Scopus
  38. B. H. McGovern, “The epidemiology, natural history and prevention of hepatitis B: implications of HIV coinfection,” Antiviral Therapy, vol. 12, supplement 3, pp. H3–H13, 2007. View at Google Scholar · View at Scopus
  39. C. T. Staples Jr., D. Rimland, and D. Dudas, “Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival,” Clinical Infectious Diseases, vol. 29, no. 1, pp. 150–154, 1999. View at Publisher · View at Google Scholar · View at Scopus
  40. K. E. Sherman, S. D. Rouster, R. T. Chung, and N. Rajicic, “Hepatitis C virus prevalence among patients infected with human immunodefidency virus: a cross-sectional analysis of the US Adult AIDS Clinical Trials Group,” Clinical Infectious Diseases, vol. 34, no. 6, pp. 831–837, 2002. View at Publisher · View at Google Scholar · View at Scopus
  41. G. Chander, J. Josephs, J. A. Fleishman et al., “Alcohol use among HIV-infected persons in care: results of a multi-site survey,” HIV Medicine, vol. 9, no. 4, pp. 196–202, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. G. Chander, B. Lau, and R. D. Moore, “Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection,” Journal of Acquired Immune Deficiency Syndromes, vol. 43, no. 4, pp. 411–417, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Thorpe, S. Saeed, E. E. M. Moodie, and M. B. Klein, “Antiretroviral treatment interruption leads to progression of liver fibrosis in HIV-hepatitis C virus co-infection,” AIDS, vol. 25, no. 7, pp. 967–975, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. M. López-Diéguez, M. L. Montes, J. F. Pascual-Pareja et al., “The natural history of liver cirrhosis in HIV-hepatitis C virus-coinfected patients,” AIDS, vol. 25, no. 7, pp. 899–904, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. B. N. Limketkai, S. H. Mehta, C. G. Sutcliffe et al., “Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV,” The Journal of the American Medical Association, vol. 308, no. 4, pp. 370–378, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. V. L. Re, J. K. Lim, M. B. Goetz et al., “Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study,” Pharmacoepidemiology and Drug Safety, vol. 20, no. 7, pp. 689–699, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. H. M. Crane, S. R. Heckbert, D. R. Drozd et al., “Lessons learned from the design and implementation of myocardial infarction adjudication tailored for HIV clinical cohorts,” American Journal of Epidemiology, vol. 179, no. 8, pp. 996–1005, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. S. J. Gange, M. M. Kitahata, M. S. Saag et al., “Cohort profile: the North American AIDS cohort collaboration on research and design (NA-ACCORD),” International Journal of Epidemiology, vol. 36, no. 2, pp. 294–301, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. H. M. Crane, B. Kestenbaum, R. D. Harrington, and M. M. Kitahata, “Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir,” AIDS, vol. 21, no. 11, pp. 1431–1439, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. A. S. Levey, L. A. Stevens, C. H. Schmid et al., “A new equation to estimate glomerular filtration rate,” Annals of Internal Medicine, vol. 150, no. 9, pp. 604–612, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. C.-T. Wai, J. K. Greenson, R. J. Fontana et al., “A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C,” Hepatology, vol. 38, no. 2, pp. 518–526, 2003. View at Publisher · View at Google Scholar · View at Scopus
  52. R. K. Sterling, E. Lissen, N. Clumeck et al., “Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection,” Hepatology, vol. 43, no. 6, pp. 1317–1325, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. W. E. Barlow, L. Ichikawa, D. Rosner, and S. Izumi, “Analysis of case-cohort designs,” Journal of Clinical Epidemiology, vol. 52, no. 12, pp. 1165–1172, 1999. View at Publisher · View at Google Scholar · View at Scopus
  54. M. M. Kitahata, B. Rodriguez, R. Haubrich et al., “Cohort profile: the centers for AIDS research network of integrated clinical systems,” International Journal of Epidemiology, vol. 37, no. 5, pp. 948–955, 2008. View at Publisher · View at Google Scholar · View at Scopus